

<b>CAR-T Therapy</b>	<b>Abecma</b> Idecabtagene vicleucel (ide-cel)	<b>Breyanzi</b> Lisocabtagene maraleucel (liso-cel)	<b>Breyanzi</b> Lisocabtagene maraleucel (liso-cel)	<b>Tecartus</b> Brexucabtagene autoleucel (brexu-cel)	<b>Yescarta</b> Axicabtagene ciloleucel (axi-cel)
<b>Indication</b>	Treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) after $\geq 4$ prior therapies, including an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody.	Treatment of relapsed or refractory large B-cell lymphoma in adults after $\geq 2$ lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B. Not indicated for the treatment of primary CNS lymphoma.	Treatment of B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse in patients up to 25 years of age. Treatment of relapsed or refractory large B-cell lymphoma in adults after $\geq 2$ lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Not indicated for treatment of primary CNS lymphoma.	Treatment of relapsed or refractory mantle cell lymphoma (MCL) in adults.	Treatment of relapsed or refractory follicular lymphoma in adults after $\geq 2$ lines of systemic therapy. Treatment of relapsed or refractory large B-cell lymphoma in adults after $\geq 2$ lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Not indicated for the treatment of primary CNS lymphoma.
<b>Black Box Warnings</b>	Cytokine release syndrome, neurologic toxicities, hemophagocytic lymphohistiocytosis/macrophage activation syndrome, prolonged cytopenia, REMS program	Cytokine release syndrome, neurologic toxicities, REMS Program			
<b>Warnings</b>	Cytomegalovirus reactivation, Hepatitis B reactivation, hypersensitivity, hypogammaglobulinemia, infections, secondary malignancies	Hepatitis B reactivation, hypersensitivity, hypogammaglobulinemia, infections, secondary malignancies			
<b>REMS</b>	<a href="http://abecmarems.com">abecmarems.com</a>	<a href="http://breyanzirems.com">breyanzirems.com</a>	<a href="http://kymriah-rems.com">kymriah-rems.com</a>	<a href="http://yescartatecartusrems.com">yescartatecartusrems.com</a>	
<b>Cost (WAC)</b>	\$420,000	\$410,000	\$475,000	\$373,000	